L
Lennart Hansson
Researcher at Uppsala University
Publications - 345
Citations - 27053
Lennart Hansson is an academic researcher from Uppsala University. The author has contributed to research in topics: Blood pressure & Essential hypertension. The author has an hindex of 56, co-authored 343 publications receiving 26505 citations. Previous affiliations of Lennart Hansson include University of Groningen & University of Michigan.
Papers
More filters
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Stevo Julius,Sverre E. Kjeldsen,Michael A. Weber,Hans R. Brunner,Steffan Ekman,Lennart Hansson,Tsushung Hua,John H. Laragh,Gordon T. McInnes,Lada Mitchell,Francis Plat,Anthony Schork,Beverly Smith,Alberto Zanchetti +13 more
TL;DR: Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period, which emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.
Journal ArticleDOI
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson,Lars H Lindholm,Leo Niskanen,Jan Lanke,Thomas Hedner,Anders Niklason,Kimmo Luomanmäki,Björn Dahlöf,Ulf de Faire,Claes Mörlin,Bengt E. Karlberg,P. O. Wester,Jan-Erik Björck +12 more
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
Lennart Hansson,Lars H Lindholm,Tord Ekbom,Björn Dahlöf,Jan Lanke,Bengt Scherstén,P. O. Wester,Thomas Hedner,Ulf de Faire +8 more
TL;DR: Old and new antihypertensive drugs were similar in prevention of cardiovascular mortality or major events, and decrease in blood pressure was of major importance for the Prevention of cardiovascular events.
Journal ArticleDOI
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
Hans Lithell,Lennart Hansson,Ingmar Skoog,Dag Elmfeldt,Albert Hofman,Bertil Olofsson,Peter Trenkwalder,Alberto Zanchetti +7 more
TL;DR: In elderly hypertensive patients, a slightly more effective blood pressure reduction during candesartan-based therapy, compared with control therapy, was associated with a modest, statistically non-significant, reduction in major cardiovascular events and with a marked reduction in non-fatal stroke.